An interventional study of Lamivudine/Zidovudine and Abacavir sulfate in HIV Infections, sponsored by Glaxo Wellcome. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Glaxo Wellcome · Not applicable, Interventional, and Treatment
The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.
In this open-label study antiretroviral-naive patients are randomized to one of two drug regimens:
Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II: Nelfinavir and Combivir.
4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.
Browse HIV Infections studies →Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients must have:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with any of the following symptoms or conditions are excluded:
Concurrent Medication:
Excluded:
Enrollment in any other investigational drug protocol.
Prior Medication:
Excluded:
Non-nucleoside reverse transcriptase inhibitors.
This study is completed, as verified in May 1999. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glaxo Wellcome